Cipla Limited
CIPLA
Classificação em ações
#1811
Cipla Limited, along with its associated entities, operates as a global... Cipla Limited, along with its associated entities, operates as a global pharmaceutical enterprise, specializing in the creation and distribution of a wide array of medicinal products. Its extensive portfolio includes both active pharmaceutical ingredients (APIs) and a diverse range of finished formulations, addressing numerous therapeutic areas such as cardiovascular diseases, metabolic disorders, HIV, respiratory conditions, urology, oncology, pediatric health, infectious diseases, critical care, hepatitis, women's health, ophthalmology, and neuropsychiatry. The company maintains a strong focus on respiratory treatments, offering various inhalers, nasal sprays, injectables, and biosimilars. Cipla has also forged significant partnerships, including a licensing arrangement with Merck & Co., Inc. for the manufacturing and commercialization of the investigational oral antiviral drug Molnupiravir, and a separate license agreement with Eli Lilly and Company for baricitinib, indicated for COVID-19. Furthermore, it collaborates with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for Molnupiravir's clinical trials. Established in 1935, Cipla's corporate headquarters are located in Mumbai, India.
Preço da ação
$14.61
Última sincronização: 2026-10-19
Valor de mercado
$11.81B
Variação (1 dia)
-0.11%
Variação (1 ano)
-21.65%
País
IN
Negociar Cipla Limited (CIPLA)
Categoria
Healthcare
Lucros da Cipla Limited (CIPLA)
Lucros em Jun 2026 TTM: $499.57M
De acordo com os últimos relatórios financeiros da Cipla Limited, os ganhos atuais da empresa são de $499.57M. Em 2024, a empresa teve ganhos de $683.63M, um aumento em relação a aos ganhos de 2023, que foram de $491.08M. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Cipla Limited de 2004 a 2026
Lucros no final de cada ano
| Ano | Lucros | Alterar |
|---|---|---|
| 2026 (TTM) | $499.57M | -37.16% |
| 2025 | $794.95M | 16.28% |
| 2024 | $683.63M | 39.21% |
| 2023 | $491.08M | 7.11% |
| 2022 | $458.50M | 2.41% |
| 2021 | $447.69M | 58.29% |
| 2020 | $282.83M | -4.75% |
| 2019 | $296.94M | 16.00% |
| 2018 | $255.98M | 36.61% |
| 2017 | $187.39M | -27.61% |
| 2016 | $258.87M | -0.84% |
| 2015 | $261.05M | -3.94% |
| 2014 | $271.76M | -29.32% |
| 2013 | $384.50M | 34.66% |
| 2012 | $285.52M | 9.46% |
| 2011 | $260.85M | -11.65% |
| 2010 | $295.26M | 67.39% |
| 2009 | $176.40M | -15.76% |
| 2008 | $209.41M | 12.35% |
| 2007 | $186.39M | 16.95% |
| 2006 | $159.38M | 35.23% |
| 2005 | $117.85M | 26.61% |
| 2004 | $93.09M | 0.00% |
Lucros de empresas semelhantes ou concorrentes
| Empresa | Lucros | Diferença de Lucros | País |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 253.21% |
IN
|
